Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Amyloidosis With or Without Heart Failure
SGLT2i therapy is associated with significant survival benefits in amyloidosis patients with HF and may offer broader advantages across the amyloidosis spectrum, including amyloid patients without heart failure.
Authors
- Simon Vanhentenrijk (ORCID: https://orcid.org/0009-0009-3358-8350)
- Wen Tang (ORCID: https://orcid.org/0000-0002-2015-7625)
- Silvio Nunes Augusto (ORCID: https://orcid.org/0000-0002-7663-4902)
- David C. Kaelber (ORCID: https://orcid.org/0000-0001-7855-9515)
- Rochell Issa (ORCID: https://orcid.org/0000-0003-4948-3210)
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- MetroHealth Medical Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- The American Journal of Medicine
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.amjmed.2025.02.010
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.06
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences